BLCM Bellicum Pharmaceuticals Inc

Price (delayed)

$3.05

Market cap

$25.61M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.94

Enterprise value

-$3.91M

Highlights
The company's debt has shrunk by 100% YoY and by 95% QoQ
BLCM's EPS has soared by 66% YoY
BLCM's revenue has shrunk by 92% YoY
The gross profit has plunged by 92% YoY

Key stats

What are the main financial stats of BLCM
Market
Shares outstanding
8.4M
Market cap
$25.61M
Enterprise value
-$3.91M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
61.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-7.82
Earnings
Revenue
$500,000
EBIT
-$34.89M
EBITDA
-$33.56M
Free cash flow
-$33.67M
Per share
EPS
-$5.94
Free cash flow per share
-$3.36
Book value per share
-$1.55
Revenue per share
$0.05
TBVPS
$3.14
Balance sheet
Total assets
$31.51M
Total liabilities
$26.33M
Debt
$58,000
Equity
-$12.86M
Working capital
$5.13M
Liquidity
Debt to equity
0
Current ratio
1.2
Quick ratio
1.14
Net debt/EBITDA
0.88
Margins
EBITDA margin
-6,711%
Gross margin
100%
Net margin
-7,313%
Operating margin
-9,933%
Efficiency
Return on assets
-71.3%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-670.6%
Return on sales
-6,977.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BLCM stock price

How has the Bellicum Pharmaceuticals stock price performed over time
Intraday
3.74%
1 week
2.35%
1 month
-8.13%
1 year
-59.55%
YTD
-13.6%
QTD
-7.58%

Financial performance

How have Bellicum Pharmaceuticals's revenue and profit performed over time
Revenue
$500,000
Gross profit
$500,000
Operating income
-$49.67M
Net income
-$36.57M
Gross margin
100%
Net margin
-7,313%
BLCM's revenue has shrunk by 92% YoY
The gross profit has plunged by 92% YoY
BLCM's net income is up by 48% year-on-year
Bellicum Pharmaceuticals's operating income has increased by 36% YoY and by 10% from the previous quarter

Growth

What is Bellicum Pharmaceuticals's growth rate over time

Valuation

What is Bellicum Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
61.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-7.82
BLCM's EPS has soared by 66% YoY
The equity has plunged by 79% YoY
BLCM's revenue has shrunk by 92% YoY
BLCM's P/S is 88% below its 5-year quarterly average of 495.8 but 82% above its last 4 quarters average of 32.4

Efficiency

How efficient is Bellicum Pharmaceuticals business performance
Bellicum Pharmaceuticals's return on assets has increased by 5% YoY

Dividends

What is BLCM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BLCM.

Financial health

How did Bellicum Pharmaceuticals financials performed over time
The total assets is 20% greater than the total liabilities
BLCM's total liabilities has dropped by 68% year-on-year but it is up by 5% since the previous quarter
The total assets has dropped by 68% year-on-year and by 22% since the previous quarter
The company's debt is 100% higher than its equity
The company's debt has shrunk by 100% YoY and by 95% QoQ
The debt to equity has soared by 100% since the previous quarter and by 100% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.